NCT07454031 2026-03-13
Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma
Peking University
Phase 1 Not yet recruiting
Clinical Trials
13 trialsNCT07455617 2026-03-06
Study of ABO2102 in KRAS-Mutated Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
Phase 1 Not yet recruiting
NCT07438782 2026-02-27
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Not yet recruiting
NCT07403721 2026-02-11
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Amgen
Phase 1 Not yet recruiting
NCT07404332 2026-02-11
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
University of Iowa
Phase 1 Not yet recruiting
NCT07368127 2026-01-26
A Study of TPD3310 in Patients With Advanced Malignant Tumors
TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.
Phase 1 Not yet recruiting
NCT06724042 2025-12-10
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1 Not yet recruiting
NCT07144085 2025-08-27
Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.
First Hospital of China Medical University
Phase 1 Not yet recruiting
NCT07057349 2025-07-09
CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer
Cytosite Biopharma Inc.
Phase 1 Not yet recruiting
NCT06956261 2025-05-04
NW-301 TCR-T in Patients With Advanced Solid Tumor
Peking University
Phase 1 Not yet recruiting
NCT06389526 2024-09-19
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
Coherus Oncology, Inc.
Phase 1 Not yet recruiting
NCT05474859 2024-07-31
Subjects With Advanced or Metastatic Solid Tumor Malignancies
Xenthera, Inc.
Phase 1 Not yet recruiting
NCT06099990 2023-10-25
Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Not yet recruiting